• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»cancer stem cells

Is Propanc Biopharma’s PRP proenzyme platform a credible challenger in the pancreatic oncology market?

By Soujanya Ravi on March 3, 2026   Pharma & Biotech  

Is Propanc Biopharma’s PRP proenzyme platform a credible challenger in the pancreatic oncology market?

Can Propanc Biopharma’s PRP therapy disrupt pancreatic cancer treatment? Explore the science, risks, and market implications of this emerging oncology approach.

What Propanc Biopharma’s PRP signals about alternative mechanisms in the crowded pancreatic cancer pipeline

By Soujanya Ravi on February 5, 2026   Pharma & Biotech  

What Propanc Biopharma’s PRP signals about alternative mechanisms in the crowded pancreatic cancer pipeline

Can PRP’s proenzyme approach change pancreatic cancer treatment strategy? Explore what Propanc Biopharma’s data means for oncology innovation.

Recent Posts

  • GlycoNex targets Prolia and Xgeva space as SPD8 meets Phase III equivalence goal
  • Could KARL STORZ’s Rubina Lens turn open surgery into the next imaging battleground?
  • Elixiron’s oral Alzheimer’s drug data raise a bigger question: can neuroinflammation become the next serious treatment target?
  • Apnimed advances oral OSA therapy case as AD109 heads toward FDA decision window
  • Optimi Health’s first UK psilocybin export signals bigger test for GMP psychedelic manufacturing
  • Why Cartesian Therapeutics’ WestGene pact could intensify the race for autoimmune cell therapy
  • Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test
  • Why TG Therapeutics’ BRIUMVI data could open a new treatment path in myasthenia gravis
  • Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets
  • Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
  • Can Zetagen’s ZetaMet Phase 2a data change how metastatic breast cancer bone lesions are treated?
  • Why Lilly’s expanded Ebglyss label could reset dosing expectations in atopic dermatitis biologics
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes